Keith Gottesdiener, Prime Medicine CEO

Prime Med­i­cine con­sid­ers fo­cus on au­toim­mune dis­eases for CAR-T, CEO says

Prime Med­i­cine is con­sid­er­ing de­vel­op­ing cell ther­a­pies for au­toim­mune dis­eases and will like­ly look for a part­ner for can­cer cell ther­a­pies, CEO Kei­th Gottes­di­ener said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.